Emergent Biosolutions (NYSE:EBS) Upgraded at Zacks Research

13 Aug 2026, 11:43 by Sarita Garza · The Markets Daily

Emergent Biosolutions (NYSE:EBS – Get Free Report) was upgraded by Zacks Research to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

EBS has been the topic of a number of other research reports. HC Wainwright lowered their target price on shares of Emergent Biosolutions from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday. UBS Group reaffirmed a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Emergent Biosolutions in a research note on Friday, August 7th. Finally, Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

View Our Latest Report on EBS

Emergent Biosolutions Stock Up 2.2%

Shares of EBS stock opened at $4.55 on Tuesday. Emergent Biosolutions has a one year low of $4.36 and a one year high of $14.06. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. The stock has a fifty day moving average price of $7.59 and a 200 day moving average price of $8.60. The stock has a market cap of $233.29 million, a P/E ratio of -1.28 and a beta of 2.35.

Emergent Biosolutions (NYSE:EBS – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. The firm had revenue of $234.30 million for the quarter, compared to analyst estimates of $177.50 million. Analysts predict that Emergent Biosolutions will post -4.63 earnings per share for the current year.

Insider Buying and Selling at Emergent Biosolutions

In related news, SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the sale, the senior vice president owned 159,098 shares in the company, valued at $1,336,423.20. This trade represents a 1.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On Emergent Biosolutions

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Emergent Biosolutions during the second quarter worth approximately $2,966,000. Globeflex Capital L P acquired a new position in shares of Emergent Biosolutions in the 2nd quarter worth approximately $2,022,000. Evolve Private Wealth LLC acquired a new position in shares of Emergent Biosolutions in the 2nd quarter worth approximately $593,000. Ieq Capital LLC bought a new stake in Emergent Biosolutions during the 2nd quarter worth approximately $488,000. Finally, Virtus Advisers LLC bought a new stake in Emergent Biosolutions during the 2nd quarter worth approximately $168,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

More Emergent Biosolutions News

Here are the key news stories impacting Emergent Biosolutions this week:

Positive Sentiment: HC Wainwright maintained a Buy rating and $10 price target. The firm projects Emergent will return to profitability in 2027, forecasting fiscal 2027 EPS of $0.28 after an estimated fiscal 2026 loss of $4.63 per share. Longer-term earnings expectations provide a potential recovery catalyst if the company stabilizes operations. HC Wainwright forecast article
Neutral Sentiment: Management’s Q2 2026 earnings call transcript is now available. Investors are likely examining the call for additional detail on the NARCAN franchise, competitive conditions, pricing, cost controls and the path toward the projected 2027 profitability. Emergent BioSolutions Q2 2026 earnings call transcript
Negative Sentiment: Emergent disclosed a $191.3 million non-cash impairment charge against its NARCAN franchise. The write-down was attributed to increased competition and pricing pressure in the naloxone market, raising concerns about the franchise’s future revenue and profitability. Levi and Korsinsky investor investigation notice
Negative Sentiment: A law firm announced an investor investigation following shareholder losses. Although the announcement does not establish wrongdoing, the investigation adds legal and reputational risk and may increase volatility.
Negative Sentiment: Near-term earnings forecasts remain weak. HC Wainwright expects losses of $0.75 per share in Q3 2026 and $0.64 in Q4 2026, reinforcing concerns that the impairment and NARCAN market pressures will continue affecting results.

About Emergent Biosolutions

(Get Free Report)

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.